To gain further insight into the clinical potential of CCI-006, we investigated its ability to sensitize MLL-r and CALM-AF10 translocated leukemia cells to chemotherapeutics currently used in the clinic to treat infant and pediatric leukemia patients. Here, KMT2A is linked to leukemia.